• Record quarterly revenue of $3.8 million, up 20% QoQ
• Full-year FY2026 revenue of $13.2 million, up 44% YoY
• Strong U.S. commercial traction with Remplir sales
• Funds available of $44.1 million as at 30 June 2026
• Remplir approved for U.S. Department of Defense and Veterans Affairs

Orthocell Ltd announced its quarterly report for the June quarter FY2026, highlighting record revenue of $3.8 million for the quarter and $13.2 million for the full year, a 44% increase from FY2025. The company's revenue growth was driven by the continued adoption of Remplir in Australia and accelerating commercial traction in the United States and new international markets. U.S. Remplir sales generated $0.33 million during the quarter, representing a 10% increase over the March quarter. Orthocell maintains a strong financial position with robust funds available of $44.1 million as at 30 June 2026, providing a strong liquidity position. The company remains focused on growing revenue, expanding manufacturing facility capacity, optimising production efficiencies, and disciplined cost management.

FY2026 revenue of $13.2 million, up 44% YoY

Orthocell expects continued growth in the 2026/2027 year, with anticipated regulatory approval for Remplir in the UK and EU and expansion in the U.S. market.